Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

Center for Computational Systems Medicine
leaf

Gene summary

leaf

Malignant transformation analysis

leaf

Malignant transformation related pathway analysis

leaf

Cell-cell communication analysis

leaf

Single-cell gene regulatory network inference analysis

leaf

Somatic mutation of malignant transformation related genes

leaf

Related drugs of malignant transformation related genes

Gene: PNRC2

Gene summary for PNRC2

check button Gene summary.

Gene informationSpeciesHuman
Gene symbol

PNRC2

Gene ID

55629

Gene nameproline rich nuclear receptor coactivator 2
Gene AliasPNRC2
Cytomap1p36.11
Gene Typeprotein-coding
GO ID

GO:0000184

UniProtAcc

A0A024RAC2


Top

Malignant transformation analysis

check button Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells
check button Malignant transformation involving gene list.
Entrez IDSymbolReplicatesSpeciesOrganTissueAdj P-valueLog2FCMalignancy
55629PNRC2HTA11_78_2000001011HumanColorectumAD3.27e-023.11e-01-0.1088
55629PNRC2HTA11_347_2000001011HumanColorectumAD3.98e-144.83e-01-0.1954
55629PNRC2HTA11_411_2000001011HumanColorectumSER3.65e-027.23e-01-0.2602
55629PNRC2HTA11_696_2000001011HumanColorectumAD1.45e-022.36e-01-0.1464
55629PNRC2HTA11_2992_2000001011HumanColorectumSER3.51e-024.86e-01-0.1706
55629PNRC2HTA11_99999970781_79442HumanColorectumMSS2.16e-105.02e-010.294
55629PNRC2HTA11_99999971662_82457HumanColorectumMSS1.28e-043.76e-010.3859
55629PNRC2LZE4THumanEsophagusESCC3.95e-122.52e-010.0811
55629PNRC2LZE7THumanEsophagusESCC1.24e-062.95e-010.0667
55629PNRC2LZE8THumanEsophagusESCC7.34e-105.57e-010.067
55629PNRC2LZE20THumanEsophagusESCC3.74e-074.36e-010.0662
55629PNRC2LZE24THumanEsophagusESCC1.14e-261.17e+000.0596
55629PNRC2LZE6THumanEsophagusESCC7.95e-053.74e-010.0845
55629PNRC2P1T-EHumanEsophagusESCC5.92e-097.07e-010.0875
55629PNRC2P2T-EHumanEsophagusESCC6.37e-541.32e+000.1177
55629PNRC2P4T-EHumanEsophagusESCC3.21e-379.23e-010.1323
55629PNRC2P5T-EHumanEsophagusESCC6.06e-062.03e-010.1327
55629PNRC2P8T-EHumanEsophagusESCC4.14e-255.62e-010.0889
55629PNRC2P9T-EHumanEsophagusESCC5.95e-205.45e-010.1131
55629PNRC2P10T-EHumanEsophagusESCC1.03e-391.04e+000.116
Page: 1 2 3 4 5 6 7 8 9 

check button Transcriptomic changes along malignancy continuum.
TissueExpression DynamicsAbbreviation
Colorectum (GSE201348)The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.FAP: Familial adenomatous polyposis
CRC: Colorectal cancer
Colorectum (HTA11)The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.AD: Adenomas
SER: Sessile serrated lesions
MSI-H: Microsatellite-high colorectal cancer
MSS: Microsatellite stable colorectal cancer
EsophagusThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ESCC: Esophageal squamous cell carcinoma
HGIN: High-grade intraepithelial neoplasias
LGIN: Low-grade intraepithelial neoplasias
LiverThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.HCC: Hepatocellular carcinoma
NAFLD: Non-alcoholic fatty liver disease
Oral CavityThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.EOLP: Erosive Oral lichen planus
LP: leukoplakia
NEOLP: Non-erosive oral lichen planus
OSCC: Oral squamous cell carcinoma
ProstateThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.BPH: Benign Prostatic Hyperplasia
ThyroidThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ATC: Anaplastic thyroid cancer
HT: Hashimoto's thyroiditis
PTC: Papillary thyroid cancer
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

check buttonFind out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer
check button Figure of enriched GO biological processes.
TissueDisease StageEnriched GO biological Processes
ColorectumADGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumSERGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSSGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSI-HGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumFAPGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
Page: 1 2 3 4 5 6 7 8 9 

check button Enriched GO biological processes.
GO IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustCount
GO:19013612ColorectumMSSorganic cyclic compound catabolic process148/3467495/187233.47e-103.18e-08148
GO:00194392ColorectumMSSaromatic compound catabolic process140/3467467/187238.56e-106.85e-08140
GO:00009561ColorectumMSSnuclear-transcribed mRNA catabolic process42/3467112/187231.75e-065.60e-0542
GO:0000184ColorectumMSSnuclear-transcribed mRNA catabolic process, nonsense-mediated decay15/346737/187231.51e-031.39e-0215
GO:0006401110EsophagusESCCRNA catabolic process204/8552278/187233.39e-215.66e-19204
GO:0034655110EsophagusESCCnucleobase-containing compound catabolic process272/8552407/187232.92e-182.90e-16272
GO:0006402110EsophagusESCCmRNA catabolic process170/8552232/187238.70e-188.00e-16170
GO:004670018EsophagusESCCheterocycle catabolic process286/8552445/187231.12e-157.47e-14286
GO:004427019EsophagusESCCcellular nitrogen compound catabolic process288/8552451/187233.03e-151.79e-13288
GO:001943918EsophagusESCCaromatic compound catabolic process295/8552467/187231.09e-145.98e-13295
GO:190136118EsophagusESCCorganic cyclic compound catabolic process307/8552495/187239.99e-144.80e-12307
GO:000095618EsophagusESCCnuclear-transcribed mRNA catabolic process88/8552112/187239.41e-134.14e-1188
GO:00903053EsophagusESCCnucleic acid phosphodiester bond hydrolysis163/8552261/187233.07e-085.73e-07163
GO:000018414EsophagusESCCnuclear-transcribed mRNA catabolic process, nonsense-mediated decay32/855237/187232.96e-074.23e-0632
GO:0110154EsophagusESCCRNA decapping14/855218/187235.77e-032.14e-0214
GO:190136111LiverCirrhoticorganic cyclic compound catabolic process213/4634495/187231.58e-193.67e-17213
GO:001943911LiverCirrhoticaromatic compound catabolic process202/4634467/187236.93e-191.28e-16202
GO:004427011LiverCirrhoticcellular nitrogen compound catabolic process195/4634451/187232.99e-184.94e-16195
GO:004670011LiverCirrhoticheterocycle catabolic process192/4634445/187237.17e-181.12e-15192
GO:003465511LiverCirrhoticnucleobase-containing compound catabolic process171/4634407/187239.07e-159.33e-13171
Page: 1 2 3 4 5 6 7 

check button Enriched KEGG pathways.
Pathway IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustqvalueCount
Page: 1 

Top

Cell-cell communication analysis

check buttonIdentification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states
LigandReceptorLRpairPathwayTissueDisease Stage
Page: 1 

Top

Single-cell gene regulatory network inference analysis

check buttonFind out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states
TFCell TypeTissueDisease StageTarget GeneRSSRegulon Activity
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.
Page: 1 

Top

Somatic mutation of malignant transformation related genes

check buttonAnnotation of somatic variants for genes involved in malignant transformation
Hugo SymbolVariant ClassVariant ClassificationdbSNP RSHGVScHGVSpHGVSp ShortSWISSPROTBIOTYPESIFTPolyPhenTumor Sample BarcodeTissueHistologySexAgeStageTherapy TypesDrugsOutcome
PNRC2SNVMissense_Mutationnovelc.334N>Gp.Ser112Glyp.S112GQ9NPJ4protein_codingdeleterious(0.02)probably_damaging(0.953)TCGA-A2-A3Y0-01Breastbreast invasive carcinomaFemale<65I/IIChemotherapyadriamycinCR
PNRC2SNVMissense_Mutationnovelc.340N>Cp.Trp114Argp.W114RQ9NPJ4protein_codingdeleterious(0)probably_damaging(0.996)TCGA-D8-A1XK-01Breastbreast invasive carcinomaFemale<65I/IIChemotherapydoxorubicine+cyclophosphamideSD
PNRC2SNVMissense_Mutationnovelc.301N>Tp.Pro101Serp.P101SQ9NPJ4protein_codingdeleterious(0.03)benign(0.144)TCGA-AX-A1C5-01Endometriumuterine corpus endometrioid carcinomaFemale<65III/IVUnspecificCarboplatinSD
PNRC2SNVMissense_Mutationnovelc.139C>Tp.His47Tyrp.H47YQ9NPJ4protein_codingtolerated(0.27)benign(0)TCGA-AX-A1CE-01Endometriumuterine corpus endometrioid carcinomaFemale<65I/IIUnspecificPaclitaxelSD
PNRC2SNVMissense_Mutationnovelc.256N>Gp.Lys86Glup.K86EQ9NPJ4protein_codingtolerated(0.78)benign(0.201)TCGA-DI-A1BU-01Endometriumuterine corpus endometrioid carcinomaFemale<65I/IIChemotherapypaclitaxelSD
PNRC2SNVMissense_Mutationnovelc.25N>Cp.Ile9Leup.I9LQ9NPJ4protein_codingtolerated(0.14)benign(0.003)TCGA-EO-A22R-01Endometriumuterine corpus endometrioid carcinomaFemale<65I/IIUnknownUnknownSD
PNRC2SNVMissense_Mutationnovelc.392N>Cp.Leu131Prop.L131PQ9NPJ4protein_codingdeleterious(0)probably_damaging(0.997)TCGA-EO-A3AV-01Endometriumuterine corpus endometrioid carcinomaFemale<65III/IVChemotherapycarboplatinCR
PNRC2SNVMissense_Mutationnovelc.185N>Ap.Gly62Glup.G62EQ9NPJ4protein_codingtolerated(0.76)probably_damaging(0.999)TCGA-EO-A3KX-01Endometriumuterine corpus endometrioid carcinomaFemale>=65I/IIUnknownUnknownSD
PNRC2SNVMissense_Mutationnovelc.185N>Tp.Gly62Valp.G62VQ9NPJ4protein_codingdeleterious(0.03)probably_damaging(0.999)TCGA-BC-A3KG-01Liverliver hepatocellular carcinomaFemale>=65I/IIUnknownUnknownPD
PNRC2SNVMissense_Mutationnovelc.111N>Cp.Lys37Asnp.K37NQ9NPJ4protein_codingtolerated(0.08)benign(0.16)TCGA-67-3771-01Lunglung adenocarcinomaFemale>=65I/IIUnknownUnknownSD
Page: 1 2 

Top

Related drugs of malignant transformation related genes

check buttonIdentification of chemicals and drugs interact with genes involved in malignant transfromation
(DGIdb 4.0)
Entrez IDSymbolCategoryInteraction TypesDrug Claim NameDrug NamePMIDs
Page: 1